Business Context and Reporting Period
This Form 8-K Current Report was filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) on September 3, 2014, covering events occurring on September 1 and September 3, 2014. The filing addresses changes to the Company's Board of Directors ahead of its annual stockholder meeting scheduled for September 4, 2014.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and contains no financial performance data.
Material Changes
- Resignation of Director: Peter Kenny resigned from the Board of Directors effective September 1, 2014, citing personal reasons. He is not standing for re-election.
- Withdrawal of Director Nominee: William A. Koefoed, Jr., a nominee for the Board, withdrew his candidacy on September 3, 2014, also citing personal reasons.
- No Disagreement: The Company explicitly states that neither departure was due to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Management Commentary
The Board of Directors does not expect to designate any substitute director nominees to replace Mr. Kenny or Mr. Koefoed for the upcoming annual stockholder meeting. No financial guidance, risk factors, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following these departures.
- Confirm the date and agenda of the annual stockholder meeting (September 4, 2014).
- Review subsequent filings to determine if the Board size was adjusted or if new nominees were added after this report.